Ravi A Madan, M.D.
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ravi A Madan, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03531827 · Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentNational Cancer Institute (NCI) · terminated · Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms · principal investigator
- Ph2NCT03315871 · Combination Immunotherapy in Biochemically Recurrent Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
- Ph2NCT03072160 · Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerNational Cancer Institute (NCI) · completed · Medullary Thyroid Cancer (MTC) · principal investigator
- Ph2NCT02649439 · Prostvac in Patients With Biochemically Recurrent Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
- Ph2NCT01875250 · Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
- Ph2NCT01867333 · Enzalutamide With or Without Vaccine Therapy for Advanced Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
- Ph2NCT01553188 · AMG 386 and Abiraterone for Advanced Prostate CancerNational Cancer Institute (NCI) · completed · Prostatic Neoplasms, Prostate Cancer, Neoplasm, Prostate · principal investigator
- Ph2NCT00942578 · A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerNational Cancer Institute (NCI) · completed · Metastatic Prostate Cancer · principal investigator
- Ph1NCT00924092 · An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...National Cancer Institute (NCI) · completed · Prostate Cancer, Breast Cancer, Lung Cancer · principal investigator
- Ph1/Ph2NCT00923247 · A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)National Cancer Institute (NCI) · terminated · Medullary Thyroid Carcinoma · principal investigator
- Ph2NCT00923130 · Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney CancerNational Cancer Institute (NCI) · completed · Renal Cell Carcinoma · principal investigator
- Ph2NCT00450463 · Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.